SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?


To: Cisco who wrote (1645)4/30/1998 11:18:00 PM
From: Sigmund  Read Replies (3) | Respond to of 1894
 
Cisco, that is interesting but why the delayed announcement?

''In addition, we are pleased that Peter P. Gombrich, a distinguished diagnostic industry professional, joined our board in March. Mr. Gombrich, the founder and former CEO of CliniCom, now a division of HBOC, is currently Chairman and CEO of Inpath and has served in the same capacity at AccuMed International.''



To: Cisco who wrote (1645)5/1/1998 9:43:00 AM
From: Frank Buck  Respond to of 1894
 
Cisco,

<<He is currently chairman and chief executive officer of InPath, LLC, located in Chicago, an in-vivo diagnostic company he founded earlier this year.>>

GOMBRICH EMPLOYMENT AND SEVERANCE AGREEMENT. Pursuant to an Employment Agreement dated August 1, 1994 between Peter P. Gombrich and AccuMed, Inc. which was assumed by the Company as a result of the merger of AccuMed, Inc. into the
Company (the "Gombrich Employment Agreement"), Mr. Gombrich served as Chairman of the Board of Directors, Chief Executive Officer and President of the Company from December 29, 1995 until he resigned on January 30, 1998. Pursuant to the Gombrich Employment Agreement, Mr. Gombrich is entitled to receive (i) initial annual compensation of $175,000 (in March 1997, the Compensation Committee increased Mr. Gombrich's annual base salary to $225,000) and (ii) a minimum annual cash bonus equal to 30% of base salary for the relevant year, and additional bonuses as determined by the Board of Directors, at its discretion. If the Company terminates Mr. Gombrich's employment without cause or Mr. Gombrich terminates his employment for good reason or at any time after 180 days following the date on which a Change of Control (as defined below) occurs, Mr. Gombrich would be entitled to a lump-sum severance payment equal to three times his annual salary. In addition, upon the occurrence of a Change of Control, any stock options held by Mr. Gombrich would immediately vest and be fully exercisable. For purposes of the Gombrich Employment Agreement, a Change of Control shall be deemed to occur if: (i) any third party directly or indirectly acquires 20% or more of the outstanding Common Stock, (ii) the Company engages in a merger, consolidation or reorganization that results in holders of Common Stock immediately prior to such transaction holding less than a majority of the voting power of the resulting entity, (iii) the Company sells all or substantially all of its assets or (iv) Mr. Gombrich's employment is terminated by the Company on a date within 90 days prior to the date on which a Change of Control occurs. The employment term was to continue until August 1, 1999. Thereafter, the term would have been automatically extended for additional one-year periods unless either party delivers notice of election not to extend the employment at least 60 days prior
to the end of the then current term.

The Company is currently negotiating a separation agreement with Mr. Gombrich. While negotiations are pending, Mr. Gombrich is serving as a consultant to the Company for which he is receiving the same salary he was entitled to under the Gombrich Employment Agreement, however, he is not receiving benefits and is not entitled to a bonus.
**********************************************************************************
Cisco between the shares of ACMI Gombrich sold (earlier last year) and the compensation of three times his annual salary that it appears he is entitled to... I think I know how he is funding his new company. Interesting that I didn't read anything about a non-competition clause.

Shareholders will be taking it on the chin again unless the separation agreement proves "just cause" . At this point I do believe that shareholders are ENTITLED to and should DEMAND answers regarding the Gombrich resignation, IE., independently tendered, requested by the Board, etc. If we are to pay Gombrich $675,000 which he can use to fund a competing diagnostic company...shareholders should be told the whole story.